MINNEAPOLIS\/ST. PAUL \u2014 Son a\u015fama gastrointestinal kanserler i\u00e7in geli\u015ftirilen ve ilk kez insan \u00fczerinde uygulanan gen d\u00fczenleme tabanl\u0131 tedavi y\u00f6ntemi, University of Minnesota\u2019dan ara\u015ft\u0131rmac\u0131lar taraf\u0131ndan ba\u015far\u0131yla tamamland\u0131. Metastatik kolorektal kanser hastalar\u0131nda uygulanan bu deneme, CRISPR\/Cas9 teknolojisiyle t\u00fcm\u00f6r i\u00e7ine s\u0131zm\u0131\u015f lenfositlerin (TIL\u2019ler) genetik olarak de\u011fi\u015ftirilmesiyle yenilik\u00e7i bir kanser tedavisinin \u00f6n\u00fcn\u00fc a\u00e7\u0131yor. The Lancet Oncology dergisinde yay\u0131mlanan \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131, bu yakla\u015f\u0131m\u0131n g\u00fcvenli oldu\u011funu ve hen\u00fcz erken a\u015famada olumlu tedavi potansiyeline sahip oldu\u011funu ortaya koydu. Bu, kolorektal kanserle m\u00fccadelede yeni bir d\u00f6nemin ba\u015flang\u0131c\u0131n\u0131 i\u015faret ediyor.<\/p>\n
Kolorektal kanserin ileri evreleri, tedavi a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck zorluklar yarat\u0131yor. D\u00f6rd\u00fcnc\u00fc evre olarak tan\u0131mlanan bu a\u015famada hastal\u0131k \u00e7o\u011funlukla tedavi edilemez durumda ve mevcut se\u00e7enekler s\u0131n\u0131rl\u0131 kal\u0131yor. Gastrointestinal onkoloji uzman\u0131 ve \u00e7al\u0131\u015fman\u0131n ba\u015f ara\u015ft\u0131rmac\u0131s\u0131 Dr. Emil Lou, bu klinik denemenin hastalar\u0131n kendi ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kullanarak metastatik t\u00fcm\u00f6r h\u00fccrelerini genetik olarak de\u011fi\u015ftirilmi\u015f T h\u00fccrelerle hedefleyen kapsaml\u0131 bir paradigm de\u011fi\u015fimi oldu\u011funu belirtiyor. Bu yenilik\u00e7i yakla\u015f\u0131m, kanser h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden ka\u00e7\u0131\u015f mekanizmalar\u0131n\u0131 a\u015fmay\u0131 ama\u00e7l\u0131yor.<\/p>\n
Ara\u015ft\u0131rman\u0131n temelini CRISPR\/Cas9 gen d\u00fczenleme sistemi olu\u015fturuyor. Bu devrimsel teknoloji, hedeflenen genom b\u00f6lgelerinde hassas de\u011fi\u015fiklikler yapabilme kapasitesine sahip. Ara\u015ft\u0131rma ekibi, TIL\u2019lerde yer alan ve T h\u00fccre aktivitesini bask\u0131layan CISH adl\u0131 bariyer g\u00f6revi g\u00f6ren i\u00e7sel ba\u011f\u0131\u015f\u0131kl\u0131k kontrol genini d\u00fczenlemeye odakland\u0131. Geleneksel antikor ya da k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rlerinin ula\u015famad\u0131\u011f\u0131 bu hedefe CRISPR arac\u0131l\u0131\u011f\u0131yla m\u00fcdahale edilmesi, T h\u00fccrelerinin t\u00fcm\u00f6rle m\u00fccadele g\u00fcc\u00fcn\u00fc a\u00e7\u0131\u011fa \u00e7\u0131karan \u00f6nemli bir ad\u0131m oldu.<\/p>\n
Faz 1 klinik \u00e7al\u0131\u015fmaya kat\u0131lan 12 ileri evre kolorektal kanser hastas\u0131na, CISH geni d\u00fczenlenmi\u015f otolog TIL\u2019ler verildi. Lenfositler t\u00fcm\u00f6rden izole edilip ex vivo olarak genetik de\u011fi\u015fime tabi tutuldu, ard\u0131ndan 10 milyardan fazla h\u00fccreye \u00e7\u0131kar\u0131l\u0131p hastalara geri verildi. Tedavi s\u00fcrecinde gen d\u00fczenleme i\u015flemiyle ili\u015fkili ciddi yan etki g\u00f6zlenmemesi, y\u00f6ntemin g\u00fcvenilir ve klinikte uygulanabilir oldu\u011funu g\u00f6sterdi. Bu geli\u015fme, CRISPR teknolojisinin ileri evre kanserlerdeki uygulamalar\u0131n\u0131n \u00f6n\u00fcn\u00fc a\u00e7\u0131yor.<\/p>\n
Deneme kat\u0131l\u0131mc\u0131lar\u0131ndan baz\u0131lar\u0131nda hastal\u0131\u011f\u0131n durmas\u0131, yani t\u00fcm\u00f6rlerin ilerlemesinin engellenmesi g\u00f6zlemlendi. \u00d6zellikle bir hastada metastatik t\u00fcm\u00f6rlerin tamamen yok oldu\u011fu ve \u00fczerinden iki y\u0131ldan fazla s\u00fcre ge\u00e7ti\u011fi belirtildi. Bu benzersiz tam yan\u0131t, gen d\u00fczenleme ile i\u00e7sel ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktalar\u0131n\u0131n hedef al\u0131nmas\u0131n\u0131n kal\u0131c\u0131 ve g\u00fc\u00e7l\u00fc antikanser etki yaratabilece\u011finin kan\u0131t\u0131 oldu. B\u00f6yle bir tamamen iyile\u015fme hali, ileri evre kolorektal kanserde daha \u00f6nce g\u00f6r\u00fclmemi\u015fti.<\/p>\n
Genome M\u00fchendislik Merkezi e\u015f direkt\u00f6r\u00fc Dr. Branden Moriarity, CISH\u2019in T h\u00fccresi resept\u00f6r sinyallerini ve sitokin cevab\u0131n\u0131 engelleyen bir i\u00e7erik g\u00f6revi g\u00f6rd\u00fc\u011f\u00fcn\u00fc a\u00e7\u0131kl\u0131yor. Bu genin h\u00fccre i\u00e7i lokasyonu, onu geleneksel kontrol noktas\u0131 inhibit\u00f6rleri i\u00e7in eri\u015filemez k\u0131lm\u0131\u015ft\u0131. CRISPR\/Cas9\u2019un kullan\u0131lmas\u0131 ise T h\u00fccrelerinde kal\u0131c\u0131 olarak bu genin i\u015flevini kaybettirerek, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin kansere kar\u015f\u0131 potansiyelini art\u0131r\u0131yor. B\u00f6ylece imm\u00fcnolojik sald\u0131r\u0131 mekanizmas\u0131 k\u00f6kten de\u011fi\u015ftiriliyor.<\/p>\n
Klasik ba\u011f\u0131\u015f\u0131kl\u0131k kontrol\u00fc engelleyicilerden farkl\u0131 olarak, bu gen d\u00fczenleme tek seferlik ve kal\u0131c\u0131 bir etki yarat\u0131yor. Ara\u015ft\u0131rma ekibinden Dr. Beau Webber, yap\u0131lan m\u00fcdahalenin T h\u00fccrelerinin DNA\u2019s\u0131na g\u00f6m\u00fcl\u00fc oldu\u011fundan, tekrarlayan doz gerektirmedi\u011fine dikkat \u00e7ekiyor. Bu durum, hastalar\u0131n tedaviye uyumunu kolayla\u015ft\u0131r\u0131yor ve ila\u00e7lar\u0131n farmakokinetik s\u0131n\u0131rlamalar\u0131n\u0131 ortadan kald\u0131r\u0131yor. Dolay\u0131s\u0131yla bu y\u00f6ntem, ba\u011f\u0131\u015f\u0131kl\u0131k terapilerinde dikkat \u00e7ekici bir kolayl\u0131k ve etkinlik sunuyor.<\/p>\n
Ba\u015far\u0131n\u0131n temel ta\u015flar\u0131ndan biri, klinik standartlara uygun, y\u00fcksek hacimde ve kaliteli genetik olarak modifiye TIL \u00fcretimi oldu. H\u00fccrelerin canl\u0131l\u0131\u011f\u0131 ve fonksiyonlar\u0131 korunarak milyarlarca h\u00fccre elde edilmesi, CRISPR tabanl\u0131 h\u00fccresel terapilerin katlanabilirli\u011fini kan\u0131tl\u0131yor. Bu s\u00fcre\u00e7, zorlu t\u00fcm\u00f6r mikro\u00e7evresine kar\u015f\u0131 kuvvetli bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisinin olu\u015fturulabilmesini sa\u011fl\u0131yor. \u00dcretim altyap\u0131s\u0131n\u0131n geli\u015ftirilmesiyle, ilerleyen d\u00f6nemde daha fazla hasta ve kanser t\u00fcr\u00fc i\u00e7in uygulama alan\u0131 yarat\u0131lmas\u0131 hedefleniyor.<\/p>\n
Buna ra\u011fmen, bu tedavinin yayg\u0131nla\u015fmas\u0131 \u00f6n\u00fcnde a\u015f\u0131lmas\u0131 gereken zorluklar bulunuyor. \u015eu anki y\u00f6ntem karma\u015f\u0131k, maliyetli ve uzman e\u011fitimine dayal\u0131. Ara\u015ft\u0131rmac\u0131lar, \u00fcretim s\u00fcre\u00e7lerini basitle\u015ftirmek, maliyetleri d\u00fc\u015f\u00fcrmek ve \u00fcretim s\u00fcresini k\u0131saltmak i\u00e7in \u00e7al\u0131\u015f\u0131yor. Ayr\u0131ca tek hastada g\u00f6zlenen tam yan\u0131t\u0131n molek\u00fcler ve h\u00fccresel nedenlerinin \u00e7\u00f6z\u00fcmlenmesi, hangi hastalar\u0131n bu tedaviden en \u00e7ok fayda sa\u011flayaca\u011f\u0131n\u0131n belirlenmesini hedefliyor.<\/p>\n
Bu klinik \u00e7al\u0131\u015fma, sentetik biyoloji ve genom m\u00fchendisli\u011finin kanser tedavisini d\u00f6n\u00fc\u015ft\u00fcrmedeki ola\u011fan\u00fcst\u00fc potansiyelini g\u00f6steriyor. H\u00fccre i\u00e7i ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktalar\u0131na do\u011frudan m\u00fcdahale edilebilmesi, imm\u00fcn h\u00fccrelerin daha hassas ve kal\u0131c\u0131 bi\u00e7imde tasarlanabilmesine olanak sa\u011flad\u0131. Bu geli\u015fme, kolorektal kanser d\u0131\u015f\u0131ndaki kanser t\u00fcrlerinde de ki\u015fiye \u00f6zel, gen d\u00fczenlenmi\u015f imm\u00fcnoterapi y\u00f6ntemlerinin geli\u015fimini h\u0131zland\u0131rabilir. Gen d\u00fczenleme ile imm\u00fcnoonkoloji kesi\u015fimi, hastalar i\u00e7in yeni umut kap\u0131lar\u0131n\u0131 aral\u0131yor.<\/p>\n
Ara\u015ft\u0131rma, Intima Bioscience biyoteknoloji firmas\u0131 taraf\u0131ndan desteklendi. Akademik d\u00fcnyan\u0131n ve end\u00fcstri partnerlerinin ortak \u00e7abas\u0131, laboratuvar ke\u015fiflerinin klinik uygulamalara d\u00f6n\u00fc\u015fmesinde kritik rol oynuyor. Bu t\u00fcr i\u015f birlikleri, \u00f6nc\u00fc tedavilerde kar\u015f\u0131la\u015f\u0131lan bilimsel ve lojistik engellerin a\u015f\u0131lmas\u0131nda temel \u00f6neme sahip. Gelecekte benzer ortakl\u0131klar\u0131n artmas\u0131 \u00f6ng\u00f6r\u00fcl\u00fcyor.<\/p>\n
University of Minnesota T\u0131p Fak\u00fcltesi ve Masonic Kanser Merkezi, bu yenilik\u00e7i tedavi alan\u0131n\u0131 geli\u015ftirerek ileriye ta\u015f\u0131maya kararl\u0131. Y\u00fcksek etkili \u00e7eviri ara\u015ft\u0131rmalar\u0131na odaklanarak, kanserle m\u00fccadelede lider konumunu s\u00fcrd\u00fcr\u00fcyor. Bu ilk klinik denemenin sonu\u00e7lar\u0131, metastatik kolorektal kanser hastalar\u0131na umut \u0131\u015f\u0131\u011f\u0131 olurken, \u00e7ok merkezli ve b\u00fcy\u00fck \u00e7apl\u0131 \u00e7al\u0131\u015fmalar i\u00e7in sa\u011flam bir temel olu\u015fturuyor.<\/p>\n
—————————-<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: \u0130nsanlar Anahtar Kelimeler<\/strong>: Gen d\u00fczenleme; Gen terapisi; Kanser tedavileri; Kanser imm\u00fcnoterapisi; Kontrol noktas\u0131 terapisi<\/p>\n","protected":false},"excerpt":{"rendered":" MINNEAPOLIS\/ST. PAUL \u2014 Son a\u015fama gastrointestinal kanserler i\u00e7in geli\u015ftirilen ve ilk kez insan \u00fczerinde uygulanan gen d\u00fczenleme tabanl\u0131 tedavi y\u00f6ntemi, University of Minnesota\u2019dan ara\u015ft\u0131rmac\u0131lar taraf\u0131ndan ba\u015far\u0131yla tamamland\u0131. Metastatik kolorektal kanser hastalar\u0131nda uygulanan bu deneme, CRISPR\/Cas9 teknolojisiyle t\u00fcm\u00f6r i\u00e7ine s\u0131zm\u0131\u015f lenfositlerin (TIL\u2019ler) genetik olarak de\u011fi\u015ftirilmesiyle yenilik\u00e7i bir kanser tedavisinin \u00f6n\u00fcn\u00fc a\u00e7\u0131yor. The Lancet Oncology dergisinde yay\u0131mlanan…<\/p>\n","protected":false},"author":1,"featured_media":4680,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[5166,5164,5163,5167,5165],"tmauthors":[],"class_list":{"0":"post-4679","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-cish-geni-duzenlemesi-ile-kanser-immunoterapisi","9":"tag-crispr-cas9-tabanli-kolorektal-kanser-tedavisi","10":"tag-gen-duzenleme-tedavisi-ileri-gastrointestinal-kanserler","11":"tag-ileri-evre-gastrointestinal-kanserlerde-klinik-crispr-denemeleri","12":"tag-metastatik-kolorektal-kanserde-t-hucre-genetik-modifikasyonu"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Yeni-Gen-Duzenleme-Tedavisi-Ileri-Gastrointestinal-Kanserlerde-1746213270.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=4679"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4679\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/4680"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=4679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=4679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=4679"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=4679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nMakale Ba\u015fl\u0131\u011f\u0131<\/strong>: Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
\nHaberin Yay\u0131n Tarihi<\/strong>: 02-May-2025
\nWeb References<\/strong>: The Lancet Oncology Article
\nDoi Referans<\/strong>: 10.1016\/S1470-2045(25)00083-X <\/p>\n